1. Home
  2. PIII vs CODX Comparison

PIII vs CODX Comparison

Compare PIII & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo P3 Health Partners Inc.

PIII

P3 Health Partners Inc.

HOLD

Current Price

$5.30

Market Cap

19.2M

Sector

Health Care

ML Signal

HOLD

Logo Co-Diagnostics Inc.

CODX

Co-Diagnostics Inc.

HOLD

Current Price

$0.39

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIII
CODX
Founded
2015
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
15.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PIII
CODX
Price
$5.30
$0.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$16.25
$2.25
AVG Volume (30 Days)
9.8K
2.1M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,444,952,000.00
$507,892.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.45
$31.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.97
$0.23
52 Week High
$14.50
$1.55

Technical Indicators

Market Signals
Indicator
PIII
CODX
Relative Strength Index (RSI) 29.58 51.18
Support Level $5.14 $0.34
Resistance Level $5.62 $0.42
Average True Range (ATR) 0.48 0.04
MACD -0.03 0.00
Stochastic Oscillator 9.86 72.45

Price Performance

Historical Comparison
PIII
CODX

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

About CODX Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Share on Social Networks: